| What is RSS feed? | About Us |
 |
 Search Score: 5/10
Source: articles.moneycentral.msn.com --- 45 days ago
NEW YORK (AP) - Shares of Amgen Inc. rose Friday after the company said a European advisory committee is in favor of approving the biotechnology company's drug Nplate, which treats a rare blood-clotting disorder. ... Source: articles.moneycentral.msn.com --- 76 days ago
NEW YORK (AP) - The biotechnology sector's third-quarter profit reports have so far been a bright spot among an otherwise volatile mix of earnings reports, helping to drive Shares of heavyweights like Amgen Inc. and Celgene Corp. on Thursday. ... Source: articles.moneycentral.msn.com --- 78 days ago
NEW YORK (AP) - Even as the broader market grew increasingly frail, Amgen Shares proved spry, bounding ahead this year on the blockbuster potential of osteoporosis drug denosumab. ... Source: articles.moneycentral.msn.com --- 95 days ago
Amgen rises on an upheld court ruling regarding two anemia drugs. Mentor Shares fall on UBS rating. ... Source: www.marketwatch.com --- 75 days ago
BOSTON (MarketWatch) -- Amgen Inc. and Bristol-Myers Squibb lead drug stocks higher early Thursday, buoyed by both companies' positive third-quarter earnings reports. The Amex Pharmaceutical Index hopped 1.9% to 257.42 and the Amex Biotechnology Index edged up 0.9% to 643.92, outpacing the Dow Jones Industrial Average . Shares of Bristol-Myers jumped 3% to $18.01 as Shares of Lilly leapt 4% to $33.23. ... Source: www.marketwatch.com --- 76 days ago
Amazon.com Shares sank late Wednesday after the online retailer delivered a weak forecast, confirming worries that the company will be hurt by sluggish economic growth and tighter consumer spending. ... Source: www.marketwatch.com --- 76 days ago
Amgen, Bristol-Myers and Lilly push drug stocks higher as Shares of drugmakers rally in the wake of largely positive earnings reports. ... Source: www.marketwatch.com --- 48 days ago
Among the companies whose Shares are expected to see active trade in ThursdayÂs session are a number of retailers  including Gymboree, Hot Topic, Limited, MenÂs Wearhouse, PetSmart and Stage -- as well as Amgen, Citi, GE, GM, Humana, Intuit, PepsiCo, Pfizer and Takeda. ...
Source: www.charlotte.com --- 7 days ago
(By DAMIAN TROISE, AP Business Writer) Sharp gains in Shares of biotechnology heavyweights mitigated the wider sector's decline in 2008. Biotech stocks proved to be one of the safest investments this year, as strong drug sales and the potential for large buyout deals defended the sector from broader market collapse. Biotech products are usually considered lifesaving necessities by patients, and thus not likely to get cut out of a budget because of a weak economy. Furthermore, with no development path paved yet for generic biologics, biotech companies don't face the same competition as their big pharma cousins. Many of the largest players, including Genentech Inc. and Amgen Inc., ended 2008 up about 23 percent and 24 percent respectively. Vertex Pharmaceuticals Inc. climbed 31 percent, Celgene Corp. 18 percent and HIV drug maker Gilead Sciences Inc. 12 percent. The substantial gains by many large biotechs offset a 16 percent loss by Biogen Idec Inc., a 65 percent loss seen in PDL BioPharma Inc. Shares and Amylin Pharmaceuticals Inc.'s 72 percent drop. The American Stock Exchange's biotechnology index, which includes several bellwether stocks, fell about 22 percent during the year. The broader Dow Jones U.S. biotechnology index shows a gain of 3 percent for the year. The sector far outperformed the Dow Jones Total Market Index, which is off 40 percent for the year, and the Standard & Poor's 500 index which is down 39 percent. One i ...
Source: seekingalpha.com --- 76 days ago
Mike Havrilla submits: Shares of Amgen (AMGN) have moved into the green in after-hours trading following a late-day Wall Street sell-off that had the Dow tanking by over 500 points. As I wrote earlier today , Amgen was able to both exceed profit and sales expectations for 3Q08 and raise its full-year profit guidance as it had done three months ago when reporting 2Q08 results. Even with the current pop in after-hours to around $54 per share, Amgen is only trading at a PE of 12X on the mid-point of its 2008 profit guidance of $4.45 to $4.55 per share.Amgen posted EPS of $1.23 versus $1.08 consensus estimates on revenue of $3.88B versus $3.7B consensus estimates. Results of key drugs for the Company include: Complete Story » ...
Source: www.schaeffersresearch.com --- 75 days ago
Shares of biotechnology concern Amgen (AMGN: sentiment, chart, options) have rallied more than 5% in electronic trading after the company reported better-than-expected third-quarter results...( Read More ) ... Source: www.bloggingstocks.com --- 76 days ago
Filed under: After the bell , Amazon.com (AMZN) , Market matters , Goldman Sachs Group (GS) , Amgen Inc (AMGN) , Electronic Arts (ERTS) , Potash Corp. of Saskatchewan (POT) Covering the stock market is almost getting as easy as it was in 1999, except that instead of predicting another up day it is the exact opposite. An end of day rally blocked most of the losses but it hardly felt that way when you sat here all day. Ultimately this too will pass, it always does. But the reasoning we are getting for this is really about the same reasoning we have used all year: recession, de-leveraging, the unknown, a poor consumer, weakening China, forced liquidations, higher taxes coming, poor earnings quality, no outlook for growth, and on and on. Since there is really nothing new to say, you just have to wonder if Warren Buffett took his own advice too much to heart as he unzipped the purse and let it all fly.... Here is the next round of miserable and unofficial closing bell levels: DJIA: 8,691.25 (+2.02%) NASDAQ: 1,603.91 (-0.73%) S&P: 908.11 (+1.26%) Amazon.com, Inc. (NASDAQ: AMZN ) was hammered after its earnings report, but amazingly enough the value buyers took it back up to flat throughout the day. The online retailer beat earnings expectations but it guided revenues down enough that it spooked those who were just looking for a conservative number and the actual earnings range offered was too wide for comfort. Shares were actually up $0.01 ...
Source: www.fiercebiotech.com --- 16 days ago
Amgen filed for marketing approval of its lead experimental drug on Friday. The biotech giant is looking for agency approval to market denosumab to treat and prevent postmenopausal osteoporosis in women, and bone loss in patients undergoing hormone therapy to treat either prostate or breast cancer. And analysts are paying close attention to the approval process. Amgen is relying on denosumab to supply the company with blockbuster revenues, crucial income as its anemia franchise loses steam. Amgen went to the FDA armed with a mountain of data. Denosumab has been tested in six late-stage trials involving 11,000 patients. And Amgen has been clear that it intends to line up a marketing partner for the drug. Some analysts tell Dow Jones that Amgen may get a partner better able to market to primary care doctors. Denosumab is injected twice yearly with no restrictions while the oral drugs available now are administered under tight guidelines. - here's Amgen's release - check out the Dow Jones report Related Articles: Amgen touts pipeline at investor meeting Amgen's Sharer sees light at end of tunnel Amgen Shares surge on positive D-mab data Wall Street swoons over Amgen's D-mab future ... Source: www.247wallst.com --- 30 days ago
24/7 Wall St. will name its annual CEO of the Year next week. The executive will be picked from a field of ten which we will profile this week The CEOs are chosen on the basis of their company’s stock market and financial performances compared with their own industry groups and all large companies traded on US markets. Only firms with market caps of more than $5 billion were considered. 24/7 reviewed revenue growth, operating margins, balance sheets, return on assets, and return on equity. At Amgen's (AMGN) recent "sit down" with analysts, the biotech company said that "Over the next five years we could have three more drugs achieve blockbuster status: Sensipar (cinacalcet), denosumab for osteoporosis and denosumab for cancer-related indications." At tall order, but Amgen has delivered before. In the last quarter, backing out charges, Amgen reported adjusted earnings of $1.23 a share versus $1.08 share. Revenue rose 7% to $3.88 billion. Both numbers beat Wall St. estimates. Over the last year, AMGN Shares are up 5% compared to a 35% drop in the DJIA. Amgen has faced significant challenges in 2007 and 2008. Epogen and Aranesp, two of the firm's important products, faced FDA challenges on safety. But, as a Morningstar analyst points out, Amgen markets four of the top 10 best-selling biologics in the world and has continued to be the strongest firm in the industry. Amgen could have had a very rough year. Kevin Scharer has kept R&D ... Source: www.topix.com --- 75 days ago
New warnings about Amgen 's blockbuster anemia drug didn't hit the biotech company as hard as Wall Street had forecast, surprising investors late Wednesday and sending the company's Shares rallying in ... ... Find more results for Amgen Shares on RSSMicro.com |
Copyright © 2008 RSSMicro.com
Earnings: Thursday Before Open Earnings: Wednesday After Close Alliance Data Systems (ADS): Q3 EPS of $0.91 misses by $0.25 . Revenue of $511M (+3.9%) vs. $524M. Shares +6% . ( PR ) Allstate (ALL): Q3 EPS of -$0.35 vs. $0.72 consensus. Revenue of $7.32B (-18.6%) vs. $6.32B. "We expect volatile financial markets and tough economic conditions to persist for some time." Shares +3.1% . ( PR ) Amazon.com (AMZN): Q3 EPS of $0.27 beats by $0.02 . Revenue of $4.26B (+30.7%) in-line. Sees Q4 revenue of $6-7B vs. $7.05B. Kindle titles now account for more than 10% of unit sales for books that are available in both digital and print formats. Shares -14% . ( PR ) Amerigroup (AGP): Q3 EPS of $0.74 beats by $0.23 . Revenue of $1.12B (+8.8%) in-line. Shares +4.7% . ( PR ) Amgen (AMGN): Q3 EPS of $1.23 beats by $0.15 . Revenue of $3.88B (+7.3%) vs. $3.7B. Shares +4.4% . ( PR ) Anadigics (ANAD): Q3 EPS of $0.00 in-line. Revenue of $58.1M (-27.9%) vs $62.8M. Sees Q4 EPS of -$0.12 to -$0.14 vs. $0.02. Shares -17.8% . ( PR ) Baidu.com (BIDU): Q3 EPS of $1.47 beats by $0.19 . Revenue of $135M (+104.2%) in-line. Shares -3% . ( PR ) Chipotle Mexican Grill (CMG): Q3 EPS of $0.59 in-line. Revenue of $340M (+18.9%) in-line. Announces a $100M share repurchase program. Shares +2.2% . ( PR ) Cirrus Logic (CRUS): FQ2 EPS of $0.15 beats by $0.06 . Revenue of $53.3M (+13.4%) vs. $52M. Shares +15.5% . ( PR ) Cohen & Steers (CNS): Q3 EPS of $0.20 misses by $0.05 ...
Filed under: Newsletters , Amgen Inc (AMGN) , Bargain stocks , Stocks to Buy There were a few stocks in 2008 that exhibited great performance despite horrible market conditions. And these gems of 2008 may provide investors with a safe haven of sorts for 2009. In fact, we are already hearing analysis of the year to come suggesting that biotechnology stocks will be the place to be for positive returns in the new year . One such name to consider is Amgen (NASDAQ: AMGN ). Founded in 1980, AMGN is one of the largest biotechnology companies in the market. It has a stable of proven drugs that provides significant profits, and a pipeline of opportunities that should provide reasonable growth in the future. Shares of AMGN have gained approximately 20% during the last year as investors recognized the value of current profits combined with future growth. Interestingly, the company really gained traction during the second half of the year as the rest of the market was imploding. Even with the gains, AMGN is a compelling investment story. Shares trade for 15 times trailing earnings and only 12 times forward earnings. That means you can buy Shares for a price-to-earnings ratio that is lower than its growth rate. One reason for the optimism in the stock in 2008 was the progress made on its osteoporosis drug, Denosumab. Analysts are expecting the drug to be a blockbuster. Denosumab has done well in trials, and AMGN recently applied for FDA appr ...
Filed under: After the bell , Microsoft (MSFT) , General Electric (GE) , PepsiCo (PEP) , Market matters , Amgen Inc (AMGN) , Suntech Power Hldgs ADS (STP) Again, what is left to say? Nothing you haven't heard before. Jobless claims were the highest in over 15 years, earnings are at risk, the recession is here, and redemptions are still coming in droves. Sorry for the gloomy attitude. Here are today's unofficial closing bell levels: DJIA: 7,552.29 (-5.56%) NASDAQ: 1,316.12 (-5.07%) S&P 500: 752.48 (-6.71%) Top Upgrades & Downgrades Amgen Inc. (NASDAQ: AMGN ) was down after it and Takeda's Millennium Pharma said that enrollment in a lung cancer trial was being suspended because of higher deaths in part of the control group over the placebo group. Shares were down over 6% at $50.13. General Electric Co. (NYSE: GE ) was slapped today on reports that the company is in talks with several private or sovereign wealth funds over capital. This stock put in a decade low, even though GE said it was not raising capital. Shares were down 11% at $12.80 right before the close. Microsoft Corporation (NASDAQ: MSFT ) filed a shelf registration statement that will allow it to sell debt instruments from time to time if it chooses, although no terms were given, no size is indicated, and no underwriters are mentioned. Shares were down 4% at $17.54 right before the close. PepsiCo, Inc. (NYSE: PEP ) reaffirmed its previously announced full-year 2008 cor ...